A Phase IV, Randomized, Open-Label, Multi-Center Study in Adults: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer) in Study V48P2E1, 5 Years After First Booster Immunization and Evaluation of Booster Kinetics in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer), 5 Years After First Booster Immunization

NCT00311493 Phase 4 COMPLETED

The purpose of this study it is to evalutate the persistence of antibodies after a booster immunisation with a TBE vaccine for adults

Details

Lead sponsor	Novartis
Phase	Phase 4
Status	COMPLETED
Enrolment	179
Start date	2006-02

Conditions

• Encephalitis, Tick-Borne

Interventions

• Tick-Borne Encephalitis vaccine

Primary outcomes

• Long-term antibody kinetics as measured both by ELISA and neutralisation test (NT) five years after first booster immunization.

Countries

Germany